Results showed that a combination of anti-PD-1/PD-L1 inhibitors and other agents may have a synergetic effect on anti-tumour activity, particularly with respect to the risk of recurrence and progression, which may be relevant for enhancing the sensitivity of other agents relative to PD-L1 negative. The gene discussed is CD274; the disease is neoplasm.